AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that the first participant has been dosed in a Phase 1 clinical trial of ACI-19764, an orally administered small molecule inhibitor of the NLRP3 inflammasome.
– ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor
– NLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and neurological diseases
– ACI-19764 is an important addition to AC Immune’s growing small molecule pipeline
– Phase 1 results in healthy volunteers are expected in H2 2026